Diffuse large B-cell lymphoma trials in Netherlands

In Netherlands 9 Also abroad 346

9 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Where
Amersfoort, Dordrecht, Leiden
Age
18 years and over
People
1,046 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06717347 · EU 2024-515566-13-00
Phase 1/2Taking people
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Where
Utrecht
Age
6 months to 25 years
People
90 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06395103 · EU 2023-507178-41-00
Phase 2Not yet taking people in Netherlands
HOVON 168:Study on epcoritamab in frail patients with diffuse large B-Cell lymphoma (DLBCL) who have not been treated before
Where
Almere, Arnhem, Delft, Deventer, Dordrecht, Emmen, Groningen, Hoofddorp, Leeuwarden, Nieuwegein, Rotterdam, 'S-Hertogenbosch, Uden, Zwolle
Age
65 years and over
People
276 worldwide
Run by
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
See details and how to join2025-524230-25-00 · EU 2025-524230-25-00
Phase 3Taking people
Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma
Where
Almelo, Amstelveen, Apeldoorn, Arnhem, Breda, Delft, Dordrecht, Eindhoven, Geleen, Goes, Groningen, Harderwijk, Hilversum, Hoofddorp, Nieuwegein, Nijmegen, Rotterdam, Schiedam, 's-Gravenhage, 's-Hertogenbosch, Sneek, Utrecht, Venlo, Zwolle
Age
18 years and over
People
324
Run by
Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT06220032 · EU 2023-505377-32-00
No phaseTaking people
The TASTY-steering Study
Where
Amsterdam, Arnhem, Dirksland, Ede, Groningen, Nijmegen, Rotterdam, Scheemda, Veldhoven, Zwolle
Age
18 years to 70 years
People
201
Run by
University Medical Center Groningen
See details and how to joinNCT07258563
Phase 1Taking people
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Where
Groningen, Nijmegen, Rotterdam, Utrecht
Age
18 years and over
People
572 worldwide
Run by
Nurix Therapeutics, Inc.
See details and how to joinNCT05131022 · EU 2023-510541-25-00
Phase 2Taking people
Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
Where
Amsterdam, Groningen, Leiden, Rotterdam
Age
18 years to 70 years
People
213 worldwide
Run by
Miltenyi Biomedicine GmbH
See details and how to joinNCT04844866 · EU 2023-506270-13-00
Phase 1Taking people
Takeda Brentuximab; Molecular Imaging of Zirconium-89-labeled Brentuximab as a Tool to Investigate brentuximab biodistribution in CD30-positive Lymphoma
Where
Groningen
Age
18 years and over
People
20
Run by
Universitair Medisch Centrum Groningen
See details and how to join2024-511151-18-01 · EU 2024-511151-18-01
Phase 1/2Taking people
Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse
Where
Amsterdam, Groningen, Maastricht, Nieuwegein, Nijmegen, Rotterdam, 's-Gravenhage, Utrecht, Zwolle
Age
18 years to 64 years
People
37 worldwide
Run by
Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT03356054 · EU 2023-510556-22-00